Table 1.

All patients' characteristics. The table shows the characteristics of all patients participating in the study. The number of patients does not always add up to 100 % (n = 212) due to missing data for some attributes.

A studied cohort of patients	Median age (years) [range]	60.92 [24–89]	%
		n = 212
Tumor type
	low-grade serous	9	4.2
	high-grade serous	162	76.4
	mucinous	11	5.2
	clear cell	9	4.2
	endometrioid	4	1.9
	Brenner	1	0.5
	borderline	1	0.5
	adenocarcinoma	4	1.9
	generalized disease	1	0.5
Grade
	1	7	3.3
	2	19	9.0
	3	165	77.8
FIGO stagea
	I	9	4.2
	II	12	5.7
	III	156	73.6
	IV	15	7.1
Residual tumorb
	yes	102	48.1
	no	90	42.5
BRCA1/BRCA2 mutationc
	yes	13	6.1
	no	199	93.9
Therapy regimen
	paclitaxel + platinum derivatives	162	76.4
	platinum monotherapy	6	2.8
	other regimend	10	4.7
	none	1	0.5
Platinum-based therapy resistance
	yes	60	28.3
	no	106	50.0
Median platinum-free interval (PFI,months) [range]
	platinum-resistant	5.31 (0–11.5)
	platinum-sensitive	29.06 (12–97)

^aFIGO (International Federation of Gynecology and Obstetrics) staging system is used for ovarian, fallopian tube, and peritoneal cancer classification.

^bResidual tumor after surgery was defined by a surgeon as “yes” (macroscopic lesions <1 cm and peritoneal metastases >1 cm), or “no” [no macroscopic residuum (R)].

^cBreast cancer 1 and 2 (BRCA1/2) germline mutations are the most frequent causes of developing hereditary OvC.

^dOther regimen [paclitaxel + platinum derivate + cyclofosfamid, cisplatin + doxorubicin, oxaliplatin + capecitabine (known as XELOX), oxaliplatin + 5-fluorouracil + folinic acid (known as FOLFOX) administered in a regimen called modified FOLFOX6, or paclitaxel + carboplatin + bevacizumab].